1.
J Neuroophthalmol
; 41(4): e718-e719, 2021 Dec 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33136685
2.
BMJ Case Rep
; 20152015 Jan 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25576512
RESUMO
Intravitreal ocriplasmin was recently approved by the Food and Drug Administration to achieve medical vitreolysis in the setting of vitreomacular adhesion (VMA). We report a case of a 76-year-old woman who developed a lamellar macular hole following treatment with intravitreal ocriplasmin injection for VMA. A pathophysiological mechanism to explain this previously unreported complication of ocriplasmin injection is proposed.